The pandemic is having a profound impact on the biotech industry and the way in which it is viewed. How will it change industry perception by the public, patients, and policymakers? What are the lessons for the public and private sectors in coordinating public health efforts both nationally and in an increasingly populous, urbanized, and interconnected world? What kind of changes can we expect to the way biomedical research is funded, organized, and its data and results communicated and shared? For the companies that rely on that research, how will product development and manufacturing change? What new approaches will be adopted to the discovery and development of therapies, vaccines, diagnostics and digital health and devices? What changes will we see in the way in which these products are regulated and delivered to patients across the world, particularly in poorer countries that struggle to compete in a global marketplace where high prices, broken supply chains and complex ordering systems have predominated?
Join Nature Biotechnology, Scientific American Worldview, and key thought leaders in the above video for a discussion around the multiplicity of issues facing the biotech industry and the opportunities they present for the post-Covid-19 world.
- Andy Marshall, PhD, Chief Editor, Nature Biotechnology
- William Hait, MD, PhD, Global Head, Johnson & Johnson External Innovation, Johnson & Johnson
- Karen Heichman, PhD, Senior Program Officer, Diagnostic Development, Innovative Technology Solutions, Global Health Division, Bill & Melinda Gates Foundation
- Johnsee Lee, MBA, PhD, Founder and CEO, Personal Genomics, Inc.
- Jeremy Levin, MB BChir, D. Phil, Chairman of the Board of Directors and Chief Executive Officer, Ovid Therapeutics Inc.
- Vicki Seyfert-Margolis, PhD, CEO & Founder, My Own Med
- Eric Topol, MD, Executive Vice-President, Scripps Research Institute; Director & Founder, Scripps Research Translational Institute, The Scripps Research Institute